Juno Therapeutics Inc (NASDAQ:JUNO)’s share price traded up 16% on Wednesday . The company traded as high as $35.00 and last traded at $32.23, with a volume of 10,966,458 shares traded. The stock had previously closed at $27.79.

A number of equities analysts have weighed in on the company. FBR & Co reissued a “buy” rating on shares of Juno Therapeutics in a research report on Monday, June 6th. Vetr lowered Juno Therapeutics from a “strong-buy” rating to a “buy” rating and set a $53.00 target price for the company. in a research report on Monday, June 6th. Zacks Investment Research lowered Juno Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, April 25th. SunTrust Banks Inc. reissued a “buy” rating and issued a $50.00 target price on shares of Juno Therapeutics in a research report on Wednesday, April 20th. Finally, Raymond James Financial Inc. assumed coverage on Juno Therapeutics in a research report on Thursday, June 2nd. They issued an “outperform” rating and a $52.00 target price for the company. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $53.11.

The stock’s 50-day moving average price is $41.00 and its 200 day moving average price is $38.26. The company’s market capitalization is $3.22 billion.

Juno Therapeutics (NASDAQ:JUNO) last issued its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.52) by $0.26. The business earned $9.80 million during the quarter, compared to analyst estimates of $4.83 million. During the same period in the previous year, the company posted ($0.30) earnings per share. Analysts predict that Juno Therapeutics Inc will post ($2.28) earnings per share for the current year.

In other Juno Therapeutics news, CEO Hans Edgar Bishop sold 90,750 shares of the firm’s stock in a transaction dated Thursday, June 9th. The stock was sold at an average price of $46.42, for a total value of $4,212,615.00. Following the completion of the sale, the chief executive officer now owns 2,704,609 shares of the company’s stock, valued at $125,547,949.78. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, General Counsel Bernard J. Cassidy sold 3,200 shares of the firm’s stock in a transaction dated Tuesday, April 19th. The stock was sold at an average price of $43.12, for a total value of $137,984.00. Following the completion of the sale, the general counsel now directly owns 57,933 shares of the company’s stock, valued at approximately $2,498,070.96. The disclosure for this sale can be found here.

Other large investors have modified their holdings of the company. BNP Paribas Arbitrage SA increased its stake in shares of Juno Therapeutics by 27.0% in the fourth quarter. BNP Paribas Arbitrage SA now owns 51,206 shares of the biopharmaceutical company’s stock valued at $2,252,000 after buying an additional 10,884 shares in the last quarter. US Bancorp DE increased its stake in shares of Juno Therapeutics by 1.8% in the fourth quarter. US Bancorp DE now owns 88,700 shares of the biopharmaceutical company’s stock valued at $3,900,000 after buying an additional 1,600 shares in the last quarter. BBR Partners LLC acquired a new stake in shares of Juno Therapeutics during the fourth quarter valued at $1,539,000. Baillie Gifford & Co. acquired a new stake in shares of Juno Therapeutics during the fourth quarter valued at $12,312,000. Finally, Stevens Capital Management LP acquired a new stake in shares of Juno Therapeutics during the fourth quarter valued at $2,315,000.

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.